LabGenius Appoints Dr. Gino Van Heeke as Chief Scientific Officer
November 29 2021 - 6:00PM
Business Wire
With over 20 years of industry experience, the
former Senior Director, Discovery and Early Development at Ablynx,
will lead LabGenius’ drug discovery and pre-clinical development
activities.
LabGenius, the machine learning (ML)-driven protein engineering
company, today announced the appointment of Gino Van Heeke Ph.D. as
Chief Scientific Officer (CSO). In this role, Gino will leverage
his wealth of drug discovery and development experience to direct
LabGenius’ scientific strategy.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211129005436/en/
Dr. Gino Van Heeke Appointed as
LabGenius' CSO (Photo: Business Wire)
“I’m extremely pleased to welcome Gino to the company as CSO,”
said Dr. James Field, Founder and CEO of LabGenius. “Gino is an
accomplished scientific leader with an impressive track record of
successfully advancing drug candidates into pre-clinical and
clinical development.”
Gino joins LabGenius from Engitix Therapeutics, where, as CSO,
he established a portfolio of projects and initiated the company’s
first drug discovery campaign. Before this, Gino was Senior
Director, Discovery and Early Development at Ablynx where he led
the discovery of NANOBODY® drug candidates and their transition to
clinical development. Prior to his move into biotech, Gino held
several senior positions at Novartis Institutes for Biomedical
Research over a 22-year tenure, including Executive Director for
Biologics.
Speaking about his appointment, Dr. Gino Van Heeke said, “The
ML-driven protein engineering platform that the team at LabGenius
has expertly built presents a tremendous opportunity to
revolutionize the way in which drugs are discovered. With solid
foundations in place, I am delighted to join the company and apply
my drug discovery knowledge and experience to ensure we use our
unique platform in the most effective way possible.”
Dr. Edwin Moses, LabGenius Chairman commented “Gino’s expertise
in translational research, coupled with LabGenius’ ML-driven drug
discovery platform, is an excellent combination which I believe
will further accelerate the company’s successful development.”
– end –
About LabGenius
LabGenius is a leading ML-driven protein engineering company,
accelerating the discovery of novel therapeutics through the
co-optimization of therapeutically valuable properties. The
company’s discovery platform, EVATM, integrates several
cutting-edge technologies drawn from the fields of computer
science, robotic automation and synthetic biology. Headquartered in
London, UK, the LabGenius team includes experts in protein
engineering, synthetic biology, software engineering, data science
and robotic automation.
For more information, please visit www.labgeni.us, or connect on
Twitter, Facebook, and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211129005436/en/
For more information, please contact: Media
enquiries: Communications Lead Lucy Shaw press@labgeni.us
Business development: Chief Operating Officer Didier Landais
didier.landais@labgeni.us